We are a diverse and dynamic team working with an international background and in collaboration with outstanding and globally recognized scientific experts to transform therapeutic approaches in oncology.




Dr. Stefan Ameres
Founder & Scientific Advisor

is a Molecular Biologist, Professor of RNA Biology at the University of Vienna, Group Leader at the Max Perutz Labs, Vienna, and Adjunct Group Leader at the Institute of Molecular Biotechnology (IMBA), Vienna. Stefan received his Ph.D. in 2006 from the University of Vienna, Austria, and conducted his postdoctoral research at the University of Massachusetts Medical School, MA, USA. He has published over forty highly regarded papers in leading journals, which have been cited more than 6000 times, and he delivered more than seventy oral presentations at international conferences. Stefan received numerous prestigious awards and grants, including the Houska Award (B&C Private Foundation, 2018) and three ERC Grants. In 2016 he was selected as an EMBO Young Investigator, and he has been an elected member of the Austrian Academy of Sciences (Young Academy) since 2015​​​​.

Dr. Johannes Zuber
Founder & Scientific Advisor

is a Medical Doctor and since 2011 Group Leader at the IMP, Vienna. Following his MD graduation in 2003 and a clinical residency at the Charité University Hospital in Berlin, Germany, he undertook postdoctoral research at Cold Spring Harbor Laboratory (CSHL), NY, USA. His outstanding scientific achievements are recorded in over 160 publications in leading peer review publications with over 8000 citations and 80 oral presentations at international conferences. Johannes has received two ERC Grants (2013, 2019), has been selected as an EMBO Young Investigator in 2014, and won the German Cancer Award (Deutscher Krebspreis) in 2016. In 2020, he has been promoted to Senior Scientist at the IMP.



Dr. Michael Bauer
Chief Executive Officer (CEO)

is an experienced biotech entrepreneur and executive with a proven track record as CEO, Board membership, and other senior R&D leadership roles in the life sciences industry. Having worked in global corporations, mid-size and small biotech companies, his focus is advancing innovative, first-in-class cancer therapeutics, including transcription factor targeting drugs, into clinical development. While most projects have reached clinical proof of concept, some have advanced to Phase 3 clinical trials and reached approval.
Prior to joining QUANTRO, Dr. Bauer was Co-founder, CEO, and a member of the Board of Directors at Cellestia Biotech AG (Basel, Switzerland), where he led the company from an early-stage academic spin-off into a pioneering oncology R&D company, closely integrating drug discovery, development and diagnostic approaches for patient selection and response tracking. Beyond advancing a novel protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex into a successful Phase 2 clinical program in oncology and autoimmune/inflammatory diseases, he led the company in building an innovative discovery pipeline for small-molecule inhibitors targeting so-far undruggable transcription factor targets in cancer. During his tenure, he raised significant funds from a global shareholder base in the EU, USA, and Asia. In his earlier career, he held management roles of increasing responsibility, gaining years of experience in leading global development projects, covering the full range of development, from preclinical research to clinical development, including IND and NDA submissions. Dr. Bauer holds a Ph.D. in Biotechnology and an M.Sc. in Chemistry.

Advisory Board

Dr. Elmar Maier
Chairman (Independent)

Dr. Sebastian Kreuz
Boehringer Ingelheim Venture Fund

Dr. Dirk Ullmann
Evotec SE

Dr. Stefan Ameres

Elmar Maier

has a long-standing track record as a seasoned deal maker in the life science industry. Over the last 25 years, he has co-founded several biotech companies (including GPC Biotech and iOmx) and held C-Level positions on multiple management teams in private and public biotech companies. Since 1999, Elmar also served as a Board member for a number of life science companies.
He has helped biotech companies to establish large R&D collaborations generating several hundred million dollars cash upfront, raise significant equity funding and execute M&A transactions.
Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, Germany. He was a scientist at the ICRF Laboratories in London and Department Head at the Max Planck Institute for Molecular Genetics in Berlin.

Sebastian Kreuz

studied Technical Biology in Stuttgart (Germany) and holds a PhD in molecular biology and immunology. With more than 15 years of experience in drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities.

Sebastian started his industrial career in 2004 by joining Boehringer Ingelheim (BI) as a research scientist in the functional genomics group, where he established novel experimental platforms based on RNAi and viral vectors for exploration of early drug targets. In the following years, Sebastian held various positions within BI’s R&D organization thereby further broadening his expertise in pharmacology and translational research.

From 2015 to 2019, Sebastian joined BI’s newly formed Research Beyond Borders department to implement a platform concept for virus-based gene therapy as a novel treatment modalitiy for BI. During this time he also established a global collaboration network in the gene therapy space with collaborations in Europe, China and the US.

Sebastian joined the BI venture fund (BIVF) in June 2019. In addition to Quantro Therapeutics, he serves as a board member of Abalos Therapeutics GmbH and Rewind Therapeutics NV.

Dirk Ullmann

has more than 22 years’ experience in drug discovery research and collaborative business. In his role as Global Head of Drug Discovery Services he oversees the operational business together with core responsibility for the scientific strategy of the company in Hit Identification, Structure-based Drug Discovery, Protein and Cellular Sciences, ADME-Tox and DMPK, Compound Management, Proteomics and Metabolomics.

Before joining Evotec he held a position as Chief Scientific Officer at Proteros, Munich after initial 11 years with Evotec before. Dirk Ullmann obtained his PhD in Chemistry and Biochemistry from the University of Leipzig, Germany on protease-catalyzed peptide synthesis and did his dost-doctoral training on protein engineering at Brandeis University, Waltham MA, (USA).

Stefan Ameres

is a Molecular Biologist and since 2012 Group Leader at the IMBA, Vienna. He received a PhD in 2004 at the Max F. Perutz Laboratories at the University of Vienna, Austria, and undertook his postdoctoral research at the University of Massachusetts Medical School, MA, USA. Stefan has published more than thirty highly regard papers in leading journals with over 3000 citations and delivered more than 60 oral presentations at international conferences. Stefan received several prestigious awards and grants, including the Houska Award (B&C Private Foundation, 2018) and three ERC Grants. In 2016 he was selected as EMBO Young Investigator, and he has been an elected member of the Austrian Academy of Sciences (Young Academy) since 2015.


Job Offers

QUANTRO Therapeutics GmbH
Dr. Bohr-Gasse 7
A-1030 Vienna, Austria

+43 122 66001

© 2023 QUANTRO Therapeutics GmbH